| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
MALVERN, PA, November 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter end... |
| 08 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 8, 2026, TELA Bio, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). As of September 8, 2026, the record date for the Special Meeting, there were 45,143,410 outstanding shares of the Company’... |
| 06 Oct 2026 |
8-K: Other Events
On October 5, 2026, TELA Bio, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Mark... |
| 05 Oct 2026 |
8-K: Other Events
MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug... |
| 29 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 28, 2026, TELA Bio, Inc. (the “Company”) entered into a Limited Consent to Credit Agreement and Guaranty (the “Limited Consent”) with Perceptive Credit Holdings V, LP, as administrative agent and collateral agent (the “Admin... |
| 18 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 31 Aug 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
Company to reduce annual operating expenses by $17.0 million or 18% |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ende... |
| 04 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 11 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
WHEREAS, the Board of Directors of TELA Bio, Inc., a Delaware corporation (the “Company”) approved and adopted the Amended and Restated 2019 Equity Incentive Plan (the “2019 Plan”) of the Company on April 20, 2020; |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MALVERN, PA, May 12, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended Ma... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
On April 29, 2026, TELA Bio, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the quarter ended March 31, 2026 of approximately $19.0 million. The Company has not yet completed its quarter-end ... |
| 24 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MALVERN, PA, March 24, 2026 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and f... |
| 20 Mar 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 14 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both (i) not material and (ii) the type of information that the Registrant treats as private or confid... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MALVERN, PA, November 13, 2025 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter end... |
| 03 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MALVERN, PA, August 11, 2025 -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the second quarter ende... |
| 02 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
MALVERN, PA – June 2, 2025 – TELA Bio, Inc. ("TELA Bio") a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Jeffrey Blizard as President ... |
Loading...